
Dec 15 (Reuters) - Immunome Inc IMNM.O:
IMMUNOME ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 3 RINGSIDE TRIAL OF VAREGACESTAT IN PATIENTS WITH DESMOID TUMORS
IMMUNOME INC - VAREGACESTAT IMPROVES PROGRESSION-FREE SURVIVAL IN PHASE 3 TRIAL
IMMUNOME INC - VAREGACESTAT ACHIEVES 56% OBJECTIVE RESPONSE RATE IN TRIAL
IMMUNOME INC - VAREGACESTAT WELL TOLERATED WITH MANAGEABLE SAFETY PROFILE
IMMUNOME INC - NDA SUBMISSION FOR VAREGACESTAT PLANNED FOR Q2 2026